Viropro, Inc. (VPRO)

[pennylessnow]

regarding SPPI: The company plans to report full Fourth Quarter and Fiscal Year ended December 31, 2010 financial results in mid-March 2011.
2011 Corporate Events and Valuation Catalysts FUSILEV ®
- FDA decision for approval of colorectal cancer indication is expected in less than three months, by April 29, 2011.
ZEVALIN ®
- Anticipate FDA decision on bioscan removal before the end of 2011.
Belinostat
- Expect data in Carcinoma of Unknown Primary trial in the second half of 2011;
- Complete enrollment in registrational study and file rolling NDA for Peripheral T-Cell Lymphoma in 2011.
Apaziquone
- Anticipate data from Phase 3 bladder cancer trials and filing NDA in 2012.